INTRASENSE SAS (ALINS.PA) Fundamental Analysis & Valuation

EPA:ALINS • FR0011179886

0.24 EUR
0 (0%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This ALINS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, ALINS scores 1 out of 10 in our fundamental rating. ALINS was compared to 12 industry peers in the Health Care Technology industry. ALINS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ALINS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. ALINS.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALINS has reported negative net income.
  • ALINS had a negative operating cash flow in the past year.
  • In the past 5 years ALINS always reported negative net income.
  • In the past 5 years ALINS always reported negative operating cash flow.
ALINS.PA Yearly Net Income VS EBIT VS OCF VS FCFALINS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -70.48%, ALINS is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
ROA -70.48%
ROE N/A
ROIC N/A
ROA(3y)-53.46%
ROA(5y)-37.03%
ROE(3y)-186.99%
ROE(5y)-123.56%
ROIC(3y)N/A
ROIC(5y)N/A
ALINS.PA Yearly ROA, ROE, ROICALINS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • Looking at the Gross Margin, with a value of 64.13%, ALINS is doing worse than 66.67% of the companies in the same industry.
  • ALINS's Gross Margin has declined in the last couple of years.
  • ALINS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.33%
GM growth 5Y-4.31%
ALINS.PA Yearly Profit, Operating, Gross MarginsALINS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ALINS.PA Health Analysis

2.1 Basic Checks

  • ALINS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALINS has been increased compared to 1 year ago.
  • ALINS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ALINS is higher compared to a year ago.
ALINS.PA Yearly Shares OutstandingALINS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALINS.PA Yearly Total Debt VS Total AssetsALINS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • ALINS has an Altman-Z score of -2.55. This is a bad value and indicates that ALINS is not financially healthy and even has some risk of bankruptcy.
  • ALINS's Altman-Z score of -2.55 is on the low side compared to the rest of the industry. ALINS is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.55
ROIC/WACCN/A
WACC7.71%
ALINS.PA Yearly LT Debt VS Equity VS FCFALINS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

2.3 Liquidity

  • ALINS has a Current Ratio of 0.39. This is a bad value and indicates that ALINS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ALINS has a Current ratio of 0.39. This is in the lower half of the industry: ALINS underperforms 75.00% of its industry peers.
  • ALINS has a Quick Ratio of 0.39. This is a bad value and indicates that ALINS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ALINS's Quick ratio of 0.39 is on the low side compared to the rest of the industry. ALINS is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.39
Quick Ratio 0.39
ALINS.PA Yearly Current Assets VS Current LiabilitesALINS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ALINS.PA Growth Analysis

3.1 Past

  • ALINS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.42%.
  • Looking at the last year, ALINS shows a quite strong growth in Revenue. The Revenue has grown by 13.56% in the last year.
  • The Revenue has been decreasing by -7.51% on average over the past years.
EPS 1Y (TTM)-56.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.79%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-18.74%
Revenue growth 5Y-7.51%
Sales Q2Q%33.25%

3.2 Future

  • The Earnings Per Share is expected to grow by 27.48% on average over the next years. This is a very strong growth
  • ALINS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 49.68% yearly.
EPS Next Y37.5%
EPS Next 2Y27.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year71.49%
Revenue Next 2Y49.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALINS.PA Yearly Revenue VS EstimatesALINS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
ALINS.PA Yearly EPS VS EstimatesALINS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALINS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALINS. In the last year negative earnings were reported.
  • Also next year ALINS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALINS.PA Price Earnings VS Forward Price EarningsALINS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALINS.PA Per share dataALINS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALINS's earnings are expected to grow with 27.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALINS.PA Dividend Analysis

5.1 Amount

  • ALINS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALINS.PA Fundamentals: All Metrics, Ratios and Statistics

INTRASENSE SAS

EPA:ALINS (3/6/2026, 7:00:00 PM)

0.24

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)09-22
Earnings (Next)03-11
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap12.65M
Revenue(TTM)2.65M
Net Income(TTM)-6.48M
Analysts40
Price Target0.24 (0%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.78
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.05
BVpS-0.02
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.13%
FCFM N/A
ROA(3y)-53.46%
ROA(5y)-37.03%
ROE(3y)-186.99%
ROE(5y)-123.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.33%
GM growth 5Y-4.31%
F-Score3
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 176.21%
Cap/Sales 71.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.39
Quick Ratio 0.39
Altman-Z -2.55
F-Score3
WACC7.71%
ROIC/WACCN/A
Cap/Depr(3y)186.16%
Cap/Depr(5y)148.72%
Cap/Sales(3y)65.28%
Cap/Sales(5y)45.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.79%
EPS Next Y37.5%
EPS Next 2Y27.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-18.74%
Revenue growth 5Y-7.51%
Sales Q2Q%33.25%
Revenue Next Year71.49%
Revenue Next 2Y49.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-57.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.49%
OCF growth 3YN/A
OCF growth 5YN/A

INTRASENSE SAS / ALINS.PA FAQ

Can you provide the ChartMill fundamental rating for INTRASENSE SAS?

ChartMill assigns a fundamental rating of 1 / 10 to ALINS.PA.


What is the valuation status for ALINS stock?

ChartMill assigns a valuation rating of 1 / 10 to INTRASENSE SAS (ALINS.PA). This can be considered as Overvalued.


What is the profitability of ALINS stock?

INTRASENSE SAS (ALINS.PA) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ALINS stock?

The Earnings per Share (EPS) of INTRASENSE SAS (ALINS.PA) is expected to grow by 37.5% in the next year.